Global Bioenergies: First milestone hit in BioMA+ project
The company announced in 2013 that the French State had granted a €5.2m "Investissements d'Avenir" financing to a consortium composed of Arkema, the CNRS and GLOBAL BIOENERGIES. The objective was to put together and demonstrate at pilot scale a complete process that would first convert renewable resources (sugar, cereals and agricultural and forestry waste) into isobutene, which would in turn be converted into methacrylic acid, a key constituent of acrylic paints. GLOBAL BIOENERGIES was granted €4m for this project and had announced in 2014 having received an initial payment of €600K.
Global Bioenergies had in this context started-up an industrial pilot in November 2014 on the agro-industrial site of Pomacle-Bazancourt. The company ARD, a subsidiary of the sugar refiner CRISTAL UNION, is in charge of the pilot's exploitation and now carries out on a weekly basis fermentation trials mimicking exploitation at full-scale.
Tony Genovesi, Global Bioenergies' manager of the BioMA+ program declares: "The process adapts well to its new industrial environment, despite it being radically different to the laboratory environment in which it has previously been developed. We have produced more isobutene in the last three months than we had over the past five years!"
The French Environment and Energy Management Agency (ADEME), who operates the "Investissements d'Avenir" program for the State, has validated the first milestone of the BioMA+ project. As a result, Global Bioenergies will soon receive a 1.7 million euro payment comprised for one third of a subsidy and for two thirds of a reimbursable advance.
Organizations
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.